Johnson & Johnson (JNJ) – Research Analysts’ Weekly Ratings Changes

Johnson & Johnson (NYSE: JNJ) recently received a number of ratings updates from brokerages and research firms:

• 10/16/2026 – Johnson & Johnson had its price target raised by Wells Fargo & Company from $275.00 to $287.00. They now have an “overweight” rating on the stock.
• 10/15/2026 – Johnson & Johnson was given a new $270.00 price target by Sanford C. Bernstein.
• 10/15/2026 – Johnson & Johnson had its price target lowered by Morgan Stanley from $294.00 to $292.00. They now have an “overweight” rating on the stock.
• 10/14/2026 – Johnson & Johnson had its price target lowered by Leerink Partners from $276.00 to $272.00. They now have an “outperform” rating on the stock.
• 10/14/2026 – Johnson & Johnson had its price target lowered by Wells Fargo & Company from $282.00 to $275.00. They now have an “overweight” rating on the stock.
• 10/14/2026 – Johnson & Johnson was given a new $270.00 price target by UBS Group AG.
• 10/14/2026 – Johnson & Johnson had its “market perform” rating reaffirmed by Sanford C. Bernstein.
• 10/14/2026 – Johnson & Johnson had its price target lowered by Royal Bank Of Canada from $290.00 to $280.00. They now have an “outperform” rating on the stock.
• 10/8/2026 – Johnson & Johnson was upgraded by Weiss Ratings from “buy (b)” to “buy (b+)”.
• 10/7/2026 – Johnson & Johnson had its “buy” rating reaffirmed by Guggenheim. They now have a $287.00 price target on the stock.
• 10/6/2026 – Johnson & Johnson had its price target raised by Royal Bank Of Canada from $287.00 to $290.00. They now have an “outperform” rating on the stock.
• 10/5/2026 – Johnson & Johnson had its price target raised by Citigroup Inc. from $298.00 to $303.00. They now have a “buy” rating on the stock.
• 9/29/2026 – Johnson & Johnson had its “neutral” rating reaffirmed by Bank of America Corporation. They now have a $278.00 price target on the stock.
• 9/29/2026 – Johnson & Johnson had its price target raised by JPMorgan Chase & Co. from $270.00 to $285.00. They now have a “neutral” rating on the stock.
• 9/22/2026 – Johnson & Johnson had its “buy” rating reaffirmed by UBS Group AG.
• 9/10/2026 – Johnson & Johnson had its price target raised by HSBC Holdings plc from $290.00 to $320.00. They now have a “buy” rating on the stock.
• 9/2/2026 – Johnson & Johnson is now covered by UBS Group AG. They set a “buy” rating and a $320.00 price target on the stock.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is 81.21%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jennifer Taubert sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 64,515 shares of company stock valued at $17,271,766. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.